Pharmacogenomics: Don't forget the children

Current Pharmacogenomics and Personalized Medicine

Volumn 6, Issue 2, 2008, Pages 77-84

  Joly, Yann ^a   Sillon, G ^a   Silverstein, T ^a   Krajinovic, M ^a   Avard, D ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Children; Ethics; Law; Pharmacogenomics; Policy

Indexed keywords

FLUOXETINE; MERCAPTOPURINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CHILD SAFETY; CHILDHOOD MORTALITY; CLINICAL PROTOCOL; CONFIDENTIALITY; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG LABELING; DRUG LEGISLATION; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; GENETIC RISK; GENETIC SCREENING; GENOTYPE; HEALTH HAZARD; HUMAN; INFORMED CONSENT; MEDICAL ETHICS; MEDICAL RESEARCH; OFF LABEL DRUG USE; PHARMACEUTICAL CARE; PHARMACOGENOMICS; PRACTICE GUIDELINE; REVIEW; SOCIAL PSYCHOLOGY;

EID: 50649117966     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/1875692110806020077     Document Type: Review

References (66)

1. American Academy of Pediatrics Committee on Bioethics. (2001) Ethical issues with genetic testing in pediatrics. Pediatrics 107(6), 1451-1455.
2. American Academy of Pediatrics (1995) Guidelines for the Ethical Conduct of Studies to Evaluate Drugs on Pediatric Populations. Pediatric 95(2), 286-294.
3. American Society of Human Genetics Board of Directors, American College of Medical Genetics Board of Directors. (1995) Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am. J. Hum. Genet. 57(5), 1233-1241.
4. Beecher, H. (1966) Ethics and clinical research. N. Engl. J. Med. 274(24), 1354-1360.
5. Blumer, J. L. (1999) Off-label uses of drugs in children. Pediatrics 104(3 Pt 2), 598-602.
6. Caldwell, P. H.; Murphy, S. B.; Butow, P. N. and Craig, J. C. (2004) Clinical trials in Children. Lancet 364(9436), 803-811.
7. Campbell, H.; Surry, S. A. and Royle, E. M. (1998) A review of randomised controlled trials published in Archives of Disease in Childhood from 1982-96. Arch. Dis. Child. 79(2), 192-197.
8. Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Social Sciences and Humanities Research Council of Canada. (1998) Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans. Online: .
9. Canadian Pediatric Society, Bioethics Committee. (2003) Guidelines for genetic testing of healthy children. Pediatr. Child Health 8(1), 42-45.
10. Civil Code of Québec, S.Q. (1991), c. 64, art. 21.
11. Clayton, E. W. (2003) Ethical, legal, and social implications of genomic medicine. N. Engl. J. Med. 349(6), 562-569.
12. Commission Regulation (EC) No 847/2000 of 27 April 2000.
13. Conroy, S.; McIntyre, J.; Choonara, I. and Stephenson, T. (2000) Drug Trial in Children: Problems and the Way Forward. Br. J. Clin. Pharmacol. 49(2), 93-97.
14. Consortium on Pharmacogenomics. (2002) Ethical and Regulatory Issues in Research and Clinical Practice. Online: .
15. Council for International Organizations of Medical Science (CIOMS). (2002) International Ethical Guidelines for Biomedical Research Involving Human Subjects. (Geneva: CIOMS). Online: .
16. Council of Europe. (2004) Additional Protocol to the Convention on Human Rights and Biomedicine Concerning Biomedical Research (Strasbourg: Council of Europe). Online: .
17. European Medicines Agency (EMEA). (2006) Guideline on Clinical Trials in Small Populations (London: EMEA). Online: .
18. Fanos, J. H. (1997) Developmental tasks of childhood and adolescence: implications for genetic testing. Am. J. Med. Genet. 71(1), 22-28.
19. Freund, C. L. and Clayton, E. W. (2003) Pharmacogenomics in children: meeting the ethical challenge. Am. J. Pharmacogenomics 3(6), 399-404.
20. Gagnon, F.; Avard, D.; Ayotte, P.; Gingras, B.; Grondin, J.; Harmsen, E. and Pereg, D. (2003) Groupes à risques particuliers. In Environnement et santé publique; Michel Gérin, Pierre Gosselin, et al., Eds.; St-Hyacinthe, Edisem Inc.: Québec, 779-820.
21. Haffner, M. E.; Whitley, J. and Moses, M. (2002) Two decades of orphan product development. Nat. Rev. Drug Discov. 1(10), 821-825.
22. Harrison, C.; Kenny, N. P.; Sidarous, M. and Rowell, M. (1997) Bioethics for clinicians: 9. Involving children in medical decisions. CMAJ. 156(6), 825-828.
23. Health Canada (2003) "Clinical Investigation of Medicinal Products in the Pediatric Population E11" (December 17) Online: .
24. Hedgecoe, A. (2004) The Politics of Personalized Medicine; University Press: Cambridge, c. 1.
25. Kanneth, A. B. (2004) Adverse drug reactions (ADRs) in children: Part I. Paediatr. Nurs. 16(6), 32-35.
26. Kauffman, R. E. and Kearns, G. L. (1992) Pharmacokinetic studies in pediatric patients. Clinical and ethical considerations. Clin. Pharmacokinet. 23(1), 10-29.
27. Knoppers, B. M.; Avard, D.; Cardinal, G. and Glass, K. C. (2002) Science and society: children and incompetent adults in genetic research: consent and safeguards. Nat. Rev. Genet. 3(3), 221-225.
28. Knoppers, B. M.; Joly, Y.; Simard, J. and Durocher, F. (2006) The emergence of an ethical duty to disclose genetic research results. Eur. J. Hum. Genet. 14(11), 1170-1178.
29. Kuehn, B. M. (2006) Laws promote pediatric drug development. JAMA 296(3), 271.
30. Leeder, J. S. (2003a) Developmental and pediatric pharmacogenomics. Pharmacogenomics 4(3), 331-41.
31. Leeder, J. S. (2003b) Pharmacogenetics and pharmacogenomics. Pediatr. Clin. N. Am. 48(3), 765-781.
32. Leeder, J. S. (2004) Translating pharmacogenetics and pharmacogenomics into drug development for clinical pediatrics and beyond. Drug Discov. Today 9(13), 567-573.
33. Lindpaintner, K. (2003) Pharmacogenomics: A New -or Not So New - Concept in Health Care. Geneva Papers 28(2), 316-330.
34. Matsui, D.; Kwan, C.; Steer, E. and Rieder, M. J. (2003) The Trials and Tribulations of Doing Drug Research in Children. CMAJ 169(10), 1033-1034.
35. Meyer, U. A. (2002) Introduction to Pharmacogenomics: Promises, Opportunities, and Limitations. In Pharmacogenomics, the Search for Individualized Therapies; Julio Licinio and Ma-Li Wong, Eds.; Weinheim: Wiley-VCH.
36. Moore, C. A.; Khoury, M. J. and Bradley, L. A. (2005) From genetics to genomics: using gene-based medicine to prevent disease and promote health in children. Semin. Perinatol. 29(3), 135-143.
37. National Consultative Bioethics Committee (CCNE). (1991) Opinion (No. 25) Regarding the Application of Genetic Testing to Individual Studies, Family Studies and Population Studies. (Problems Related to DNA "Banks", Cell "Banks" and Computerisation) (Paris: CCNE). Online: .
38. Nuffield Council on Bioethics (2003). Pharmacogenetics Ethical Issues (London: Nuffield Council on Bioethics) Online: .
39. Omenn, G. S. and Motulski, A. G. (2003) Integration of Pharmacogenomics into Medical Practice. In Pharmacogenomics: Social, Ethical and Clinical Dimensions; Rothstein, M. A.; Ed.; Hoboken: John Wiley & Sons, pp. 137.
40. Orphan Drug Act, Title 21. United States Code (USC) Section 360ee.
41. Patenaude, A. F.; Sénécal, K. and Avard, D. (2006) Whither Pediatric Research and Predisposition Genetic Testing? GenEdit. 4(2), 1-9.
42. Pinsky, L.; Atkins, D.; Ramsey, S. and Burke, W. (2003) Developing Guidelines for the Clinical Use of Genetic Tests: A U. S. Perspective. In Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease; Khoury, M.; Little, J.; Burke, W. Ed., Oxford: Oxford University Press, UK.
43. Pirmohamed, M. and Lewis, F. (2004) The Implications of Pharmacogenetics and Pharmacogenomics for Drug Development and Health Care. In Regulating Pharmaceuticals in Europe: Striving For Efficiency, Equity and Quality; Mossialos, E.; Mrazek, M.; Walley, T. Ed.; Cambridge: Open University Press, UK.
44. Rai, A. K. (2002) Pharmacogenetic Interventions, Orphan Drugs and Distributive Justice: The Role of Cost Benefit Analysis. Soc. Philos. Policy 19(2), 246-270.
45. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for pediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004.
46. Roberts, R.; Rodriguez, W.; Murphy, D. and Crescenzi, T. (2003) Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. JAMA 290(7), 950-951.
47. Roden, D. M. and George, A. L. (2002) The genetic basis of variability in drug responses. Nat. Rev. Drug Discov. 1(1), 37-44.
48. Ross, L. F. (2006) Children in Medical Research: access versus protection; Oxford University Press: New York.
49. Royal College of Pediatrics, Child Health: Ethics Committee. (2000) Guidelines for the ethical conduct of medical research involving children. Arch. Dis. Child. 82, 177-182.
50. Saint-Raymond, A. and Brasseur, D. (2005) Development of medicines in Europe for children. Paediatr. Respir. Rev. 6(1), 45-51.
51. Shaefer, L. (2007) "New EU Rule Makes Medication Safer for Kids" Deusche Welle (May 1) Online: .
52. Skolbekken, J. A.; Ursin, L.; Øystein; Solberg, B.; Christensen, E. and Ytterhus, B. (2005) Not worth the paper it's written on? Informed consent and biobank research in a Norwegian context. Crit. Public Health 15(4), 335-347.
53. Smart, A.; Martin, P. and Parker, M. (2004) Tailored Medicine: Who Will it Fit? The Ethics of Patient and Disease Stratification. Bioethics 18(4), 322-342.
54. Smyth, R. L. (2001) Research with children: pediatric practice needs better evidence - gained in collaboration with parents and children. BMJ 322, 1377-1378.
55. Steinbrook, R. (2002). Testing medications in children. N. Engl. J. Med. 347(18), 1462-1470.
56. Stipp, D. (2001) A DNA Tragedy. Fortune 142(10), 170-174.
57. Subpart, D. Additional DHHS Protections for Children Involved as Subjects in Research. 48 FR 9818, March 8, 1983; 56 FR 28032, June 18, 1991.
58. Sutcliffe, A. G. (1999) Prescribing medicines for children: major problems exist - but there are some promising developments. BMJ 319, 70-71.
59. The Code of Nuremberg Permissible Medical Experiments Trials of War Criminals before the Nuremberg Military Tribunals under Control Council Law No. 10; Nuremberg, October 1946-1949, Vol. 2, 181-182 (US Government Printing Office, Washington DC, USA, 1949).
60. The Pediatric Research and Equity Act. (2003) Public Law No: 108-155.
61. The Québec Network of Applied Human Genetics (RMGA) (2002) Statement of principles: Human Genomic Research, (Montréal: RMGA). Online: .
62. Un General Assembly. (1990) Convention on the Rights of the Child, Adopted and opened for signature, ratification and accession by General Assembly resolution 44/25 of 20 November 1989, entry into force 2 September 1990, in accordance with article 49.
63. Wang, L. and Weinshilboum, R. (2006) Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 25(11), 1629-38.
64. Williams-Jones, B. and Ozdemir, V. (2008) Challenges for Corporate Ethics in Marketing Genetic Tests. J. Bus. Ethics 77(1), 33-44.
65. World Medical Association. (1964) Declaration of Helsinki, Ethical Principles for Medical Research involving Human Subjects, (Helsinki, 1964, amended in 1975, 1983, 1989, 1996, 2000, 2002 and 2004). Online: .
66. Zimmerman, R. (2002) Desperately seeking kids for clinical trials. Wall St. J. D1, D6.